A new development in the analysis of cancer has been announced by Agilent Technologies. The company has reported an innovative method that enables the rapid advance of microarray-based comparative genomic studies in cancer. According to the report published in the December 24, 2004 issue of the Proceedings of the National Academy of Science (PNAS) in collaboration with the National Human Genome Research Institute, Agilent has developed a specialised microarray platform that uses total genomic DNA to overcome several scientific hurdles that previously impeded comparative genomic studies in cancer.
Chromosomal changes in
cancer can be studied using Comparative genomic hybridization (CGH),
which undergoes dramatic chromosomal changes, including loss,
duplication and the translocation of DNA from one chromosome to
another, as cancer develops. Understanding these changes is key to
understanding cancer progression as well as developing possible
therapies and prognostic and diagnostic tools.
"Genomic alterations leading to changes in the number of gene copies
present in cells are important events in the genesis and progression of
cancer," said Michael Bittner of the Translational Genomics Research
Institute. "Agilent has now taken array-CGH experiments into a new
realm of resolution, sensitivity, and reproducibility that allows
reliable detection of alterations at the scale of individual genes and
even introns and exons. This advancement, along with the possibility it
provides to correlate genomic copy alterations with mRNA abundance and
protein abundance, is going to incite a huge body of experimentation
and publication among the cancer research community."
In the past, comparative genomic hybridization was performed through
the optical imaging of whole chromosomes, a technique with limited
sensitivity, resolution, quantification and throughput. Efforts in
recent years to use microarrays to overcome these limitations have been
hampered by inadequate sensitivity, sp
ecificity and flexibility of the
microarray platforms. As detailed in the PNAS paper, Agilent's
breakthrough is founded on the modification of its gene-expression
profiling microarray technology to improve its utility for DNA analysis
applications. This new platform provides high sensitivity, enabling CGH
researchers to reliably identify the single copy deletions in
chromosomes that have been the most difficult to detect.
Additionally, the technology allows for the use of total genomic DNA to
detect chromosomal changes across the entire genome. The Platform
enables amplification or non-amplification of total genomic DNA in
studies of the whole genome, providing better ease of use and improved
experimental design.
'"/>
Source:OBBeC
Related biology news :
1. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
2. Breakthrough method in nanoparticle synthesis paves the way for new pharmaceutical and biomedical applications
3. Breakthrough isolating embryo-quality stem cells from blood
4. Breakthrough System for Understanding Ocean Plant Life Announced
5. Breakthrough: Scientists create worlds tiniest organic particles
6. Breakthrough in micro-device fabrication combines biology and synthetic chemistry
7. Sciences Breakthrough of the Year: Watching evolution in action
8. Breakthrough for stem cell research
9. Breakthrough in understanding type-2 diabetes as key genes identified
10. Breakthrough vaccine to treat chemo-resistant ovarian cancer
11. Affymetrix Licenses Microfluidics Technology From Caliper Life Sciences
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |